Changes for page Ajanta Pharma Ltd

Last modified by Asif Farooqui on 2021/03/15 15:40
From version < 2.3 >
edited by Asif Farooqui
on 2020/10/07 20:49
To version < 4.1 >
edited by Asif Farooqui
on 2020/10/08 14:51
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -72,10 +72,8 @@
72 72  
73 73  == International business ==
74 74  
75 -Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa.
75 +Total sales from international business for FY 2020 stood at H 1,790 cr. against H 1,324 cr. in the previous year, a growth of 35%. It was primarily backed by robust growth of 82% in the US market and strong growth in branded generics at 27% in Asia and 14% in Africa. Company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
76 76  
77 -As explained in Exhibit 4 and Exhibit 5, company’s exports revenues are contributed by well-diversified markets, avoiding over dependence on any single market.
78 -
79 79  = Financial highlight =
80 80  
81 81  April 30, 2020 Ajanta Pharma Ltd. reported performance for the 4 th quarter & financial year ended 31 st March 2019.{{footnote}}http://www.ajantapharma.com/AdminData/Results/PressReleaseandResultQ4FY2019.pdf{{/footnote}}
... ... @@ -103,8 +103,8 @@
103 103  **Q4 FY 2019, total export sales were Rs. 343 cr. (against Rs. 348 cr.) posting de-growth of 1%.**
104 104  
105 105  * Emerging Market branded generic sale was Rs. 221 cr. (against Rs. 243 cr.) posting 9% de-growth. Out of which:
106 -* Africa branded generic sale was Rs. 75 cr. (against Rs. 109 cr.) posting 31% degrowth.
107 -* Asia branded generic sale was Rs. 143 cr. (against Rs. 132 cr.) posting 9% growth.
104 +** Africa branded generic sale was Rs. 75 cr. (against Rs. 109 cr.) posting 31% degrowth.
105 +** Asia branded generic sale was Rs. 143 cr. (against Rs. 132 cr.) posting 9% growth.
108 108  * US generic sale was Rs. 76 cr. (against Rs. 42 cr.) posting 79% growth.
109 109  * Africa Institution sale was Rs. 46 cr. (against Rs. 63 cr.) posting 26% de-growth.
110 110  
This site is funded and maintained by Fintel.io